EPAS1 and renal cell carcinoma: Indeed, since the VHL gene mutation was cloned in ccRCC patients, a few key drugs that targeted the VHL gene have developed.13, 14, 15, 16 For example, HIF-2α inhibitor PT2385 targeting VHL gene mutation has obtained 66% overall Disease Control Rate (DCR) in 51 RCC patients.17